Metastatic biomarkers of oral squamous cell carcinoma and their applications
By detecting the serum content of CXCL16 protein, the problem of convenience and accuracy of detection in the diagnosis of metastatic diagnosis of oral squamous cell carcinoma is solved, and a more convenient detection method is provided, which significantly improves the metastatic detection of oral squamous cell carcinoma. effect.
Patent Information
- Application Number
- CN202410783836.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-18
AI Technical Summary
The prior art is used for the diagnosis of metastatic diagnosis of oral squamous cell carcinoma, which has problems such as long time, complex operation and great harm to patients, making it difficult to improve the convenience and accuracy of detection.
Using CXCL16 protein as a biomarker, by detecting the content of sCXCL16 protein in the patient's serum, it predicts whether oral squamous cell carcinoma is metastatic, providing a more convenient detection method.
Effectively improve the convenience and accuracy of metastatic detection of oral squamous cell carcinoma and reduce harm to patients. The high expression of CXCL16 protein is significantly related to the metastatic properties of cancer, which can play a key role in diagnosis, treatment and monitoring. .
Smart Images

Figure CN118362728B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to biomarkers of oral squamous cell carcinoma metastasis and applications thereof. Background Art
[0002] At present, the incidence of oral cancer is gradually increasing, among which oral squamous cell carcinoma (OSCC) is the most common pathological type. OSCC is a highly invasive malignant tumor, and metastasis is an important cause of high mortality caused by cancer. At present, the metastatic diagnosis of oral squamous cell carcinoma is mainly based on surgical or biopsy evaluation, such as surgical peripheral lymph node dissection or non-surgical puncture to obtain lymph nodes, and then confirm whether it is metastatic through pathological examination. The above detection methods take a long time, the sampling and detection operations are complicated, and it will cause certain harm to the patient's body.
[0003] It can be seen that the existing technology still needs to be improved and enhanced. Summary of the invention
[0004] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide a biomarker for detecting metastasis of oral squamous cell carcinoma and its application, aiming to improve the convenience of detecting metastasis of oral squamous cell carcinoma.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] The present invention provides an application of a biomarker in preparing a product for detecting the metastasis of oral squamous cell carcinoma, wherein the biomarker comprises CXCL16 protein.
[0007] Beneficial effects: The present invention provides a biomarker for detecting metastasis of oral squamous cell carcinoma and its application, wherein the biomarker includes CXCL16 protein. In patient samples with lymph node metastasis, the level of CXCL16 protein is significantly higher than that in patient samples without lymph node metastasis, and sCXCL16 protein can significantly promote the metastasis of oral squamous cell carcinoma (OSCC) cells. By detecting the CXCL16 protein content in the sample, it is possible to effectively predict whether oral squamous cell carcinoma is metastatic. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 This is a graph showing the difference in CXCL16 gene expression between normal tissue and oral squamous cell carcinoma tissue.
[0009] Figure 2 This is a graph showing the difference in CXCL16 expression between in situ tumor tissue and metastatic tumor tissue.
[0010] Figure 3 Figure 2 is a graph showing the relationship between the N stage of OSCC patients and the expression level of CXCL16.
[0011] Figure 4 The results of immunohistochemical staining.
[0012] Figure 5 Scoring results for immunohistochemical staining.
[0013] Figure 6 Serum sCXCL16 concentrations in node-negative and node-positive OSCC patients.
[0014] Figure 7 The expression of sCXCL16 in orthotopic and metastatic OSCC cell lines was scored.
[0015] Figure 8 This is the cell migration staining result of the cell migration experiment.
[0016] Fig. 9 Cell number counting results for cell migration experiment.
[0017] Fig.10 This is the survival curve of OSCC patients.
[0018] Fig.11 Figure 2 is the relationship between overall survival events and CXCL16 gene expression.
[0019] Fig.12 Figure 2 is a graph showing the relationship between disease-related survival events and CXCL16 gene expression. DETAILED DESCRIPTION
[0020] The present invention provides a biomarker for metastatic oral squamous cell carcinoma and its application. In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the accompanying drawings and examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0021] The present invention provides an application of a biomarker in preparing a product for detecting the metastasis of oral squamous cell carcinoma, wherein the biomarker comprises CXCL16 protein.
[0022] CXCL16 is a chemokine that is mainly expressed in various cancer cells, dendritic cells, macrophages and endothelial cells. CXCL16 can exist in a membrane-bound form and as a secreted soluble molecule sCXCL16. In a preferred embodiment of the present invention, by detecting the sCXCL16 protein content in the patient's serum, it is possible to effectively detect whether OSCC has metastatic potential. Compared with existing puncture sampling detection methods, the detection is more convenient and causes the least harm to the patient.
[0023] The following related experiments are used to prove that CXCL16 protein expression is correlated with OSCC metastasis.
[0024] Experiment 1: Analysis of CXCL16 expression level
[0025] Methods: The mRNA, clinical, and genomic data of oral squamous cell carcinoma (OSCC) patients and normal oral tissues were obtained from The Cancer Genome Database (TCGA) (https: / / portal.gdc.cancer.gov / ) and Cancer Cell Line Encyclopedia (CCLE) (https: / / portals.broadinstitute.org / ccle), respectively, and the above data were analyzed.
[0026] See also Figure 1 ,The results showed that the expression level of CXCL16 in OSCC tissues was significantly increased compared with normal tissues (***p<0.001), suggesting that it may play an important role in the pathogenesis of OSCC.
[0027] See also Figure 2 ,Further analysis revealed that the expression level of CXCL16 was higher in metastatic OSCC compared with in situ OSCC (**p<0.01), indicating that CXCL16 may be associated with the invasiveness and metastatic ability of OSCC.
[0028] Based on the above results, the Kaplan-Meier method was further used to perform survival analysis on OSCC patients, and the variability of CXCL16 gene expression between tumor grades was represented by a box plot. The results are shown in Figure 3 shown.
[0029] Figure 3 The figure shows the relationship between the N stage of OSCC patients and the expression level of CXCL16. The analysis results show that with the increase of N stage, the expression level of CXCL16 increases (**p<0.01, ***p<0.001), which further emphasizes the possible role of CXCL16 in the progression of OSCC.
[0030] Experiment 2: Immunohistochemical Analysis
[0031] Patient samples were further obtained for verification, and immunohistochemical analysis was performed on OSCC patient samples with lymph node metastasis and OSCC patient samples without lymph node metastasis. The steps of immunohistochemical analysis were as follows:
[0032] 1. Sample preparation: After obtaining the sample tissue, quick freeze it, place the tissue block flat in a clean small box, add OCT embedding agent to soak the tissue, add liquid nitrogen to quick freeze, and quickly freeze it into a block in about 10 to 20 seconds. Clamp the frozen tissue block on the slicer holder, start the coarse advance and retract key, turn the knob to flatten and fix the tissue; then place the cryostat in a low-temperature sealed room and cut thin slices (5 to 10 microns) continuously;
[0033] 2. Antigen repair: Antigen repair by microwave treatment;
[0034] 3. Incubate overnight with anti-CXCL16 antibody (Invitrogen, MA5-27845, USA) and wash; the dilution of the antibody is 1:200;
[0035] 4. Then add HRP horseradish peroxidase (mouse source) as the labeled secondary antibody. After incubation with the secondary antibody for 2 hours, wash with PBS 3 to 5 times;
[0036] 5. Use DAB (dihydrobenzothiazoline-3,3'-oxide) as a color substrate and add it to the tissue section, then observe. Once the color development reaches the desired level, place it in PBS to stop the color development reaction to avoid over-staining;
[0037] 6. Washing: After the color development reaction is completed, another washing step is required to remove unreacted substrate and other non-specific binding substances;
[0038] 7. Dehydration and sealing: After washing, the tissue sections are sequentially immersed in different concentrations of ethanol to achieve dehydration, and then sealed on the slide using hyaluronate;
[0039] 8. Microscopic examination: The expression of CXCL16 in OSCC tissues and cells was observed and analyzed using a microscope (Nikon, Japan).
[0040] The staining results are as follows Figure 4 As shown, Figure 4 In the experiment, CXCL16 protein was stained brown or brownish yellow. Figure 4 It can be seen that compared with the samples without lymph node metastasis, the positive lymph node samples showed more brown or brownish yellow after staining. The staining intensity was scored as 0 (negative), 1 (1+), 2 (2+), and 3 (3+). The staining positive rate was calculated, and the product of the "staining intensity score" and the "staining positive rate" was the total score, and the total score was used as the staining result. Figure 5 This is the immunohistochemical staining scoring result. The scoring results show that the staining intensity of CXCL16 protein in positive lymph node samples is significantly higher than that in samples without lymph node metastasis (**p<0.01).
[0041] Experiment 3: Analysis of sCXCL16 secretion in serum
[0042] Serum from lymph node-negative and lymph node-positive OSCC patients was collected and the sCXCL16 concentration was detected using an ELISA kit. Figure 6 shown.
[0043] from Figure 6 It can be seen that compared with lymph node-negative OSCC patients, lymph node-positive OSCC patients have significantly higher CXCL16 secretion (***p<0.001), reflecting that the sCXCL16 concentration in patient serum is associated with the metastasis of OSCC.
[0044] The in situ OSCC cell lines and metastatic OSCC cell lines were further analyzed based on the Cancer Cell Line Encyclopedia (CCLE) (https: / / portals.broadinstitute.org / ccle) database, and their sCXCL16 expression levels were scored. The scoring results are as follows: Figure 7 As shown, the results showed that the sCXCL16 score of OSCC cell lines that underwent metastasis was significantly higher (*p<0.05).
[0045] Experiment 4: Cell migration assay
[0046] The cell migration experiment was performed using a transfer chamber with a polycarbonate membrane, with a control group and a group with sCXCL16 added;
[0047] Upper chamber planting 1×10 5 cells, the lower chamber of the control group was supplemented with DMEM medium, and the lower chamber of the sCXCL16-added group was supplemented with DMEM medium containing sCXCL16 (150 ng / ml);
[0048] Specifically, the DMEM medium contained 10% fetal bovine serum (Gibco, USA), 100 units / ml penicillin and 100 μg / ml streptomycin. 2 The cells were incubated at 37°C in a humidified incubator. After incubation, the cells on the top surface of the membrane were removed, and the cells remaining on the lower surface were stained with crystal violet at room temperature. Subsequently, the cells were observed under an optical microscope (Nikon, Japan). The cells in 5 random fields were counted and the average value was obtained.
[0049] Figure 8 For cell staining results, Figure 8It can be seen that as the incubation time increases, the number of cells under the membrane in the group with sCXCL16 added increases. Although the number of cells in the control group also increases, the degree of increase is obviously not as high as that in the group with sCXCL16 added. Fig. 9 The results of cell number counting show that the addition of sCXCL16 (150ng / ml) increased cell migration. Compared with the control group, the difference reached a significant level after 12 hours, and the difference increased further after 24 hours (****p<0.0001). This verifies the role of CXCL16 in promoting the migration ability of OSCC cells.
[0050] Experiment 5. Analysis of CXCL16 expression and patient survival
[0051] 1. Based on the analysis of TCGA-HNSC dataset, OSCC patients were divided into high expression group and low expression group according to the expression level of CXCL16, and the survival curves of the two groups were drawn. Fig.10 This is the survival curve of OSCC patients. The difference in survival curves between the high expression group and the low expression group was statistically significant (P=0.029).
[0052] 2. Based on the analysis of TCGA-HNSC data set, the relationship between survival and death events and CXCL16 expression level was further analyzed. The analysis results are as follows Fig.11 and Fig.12 shown.
[0053] Fig.11 Figure 2 is a graph showing the relationship between overall survival events and CXCL16 gene expression. It can be seen from the figure that high expression of CXCL16 is associated with a shorter overall survival time (*p<0.05).
[0054] Fig.12 Figure 2 is a graph showing the relationship between disease-related survival events and CXCL16 gene expression. It can be seen from the figure that high expression of CXCL16 is associated with a shorter disease-specific survival time (***p<0.001).
[0055] In summary, the present invention has demonstrated through the above multiple experiments and data analysis that the expression level of CXCL16 is correlated with the metastasis of OSCC, and can be used as a biomarker for OSCC metastasis, and can also play a key role in diagnosis, treatment and patient monitoring.
[0056] In addition, the above experiments also proved that sCXCL16 in serum can reflect whether OSSC is metastatic. When preparing a kit for oral squamous cell carcinoma metastasis, the concentration of sCXCL16 in the patient's serum can be detected and compared with the concentration of the negative control, so as to quickly and accurately determine whether OSCC is metastatic.
[0057] It is understandable that those skilled in the art can make equivalent substitutions or changes based on the technical solution and inventive concept of the present invention, and all these changes or substitutions should fall within the protection scope of the claims attached to the present invention.
Claims
1. Use of a biomarker in the preparation of a product for detecting metastasis of oral squamous cell carcinoma, characterized in that: The biomarkers include CXCL16 protein.
